Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics

Fineline Cube Jul 3, 2026
Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China

Fineline Cube Jul 3, 2026
Company Drug

Edding Genor’s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib/II Breast Cancer Trial, Targeting TNBC and HR+/HER2- Subtypes

Fineline Cube Jul 3, 2026
Company Deals

Macera Therapeutics and Innorna Co., Ltd Collaborate on CAR-M mRNA-LNP Technology

Fineline Cube May 11, 2024

Macera Therapeutics, a company based in Nanjing specializing in the development of macrophage immunotherapies, has...

Company Deals

Vazyme Biotech and SPH KDL Health Join Forces to Promote Alzheimer’s Blood Tests

Fineline Cube May 11, 2024

Vazyme Biotech Co., Ltd (SHA: 688105), a prominent biotech company based in China, has entered...

Company Medical Device

Jiangsu BioPerfectus’ Dengue Detection Kit Gains NMPA Approval for Commercialization

Fineline Cube May 11, 2024

Jiangsu BioPerfectus Technologies Co., Ltd (SHA: 688399), a leading in vitro diagnostic (IVD) product manufacturer...

Company Deals

DSciLab, mRNA Pharma Startup, Bags RMB 100 Million in Angel Financing Led by Fosun Health

Fineline Cube May 11, 2024

DSciLab Co., Ltd, a China-based mRNA pharmaceutical company nurtured by Fosun Health Capital, has announced...

Company Deals

Novo Nordisk Partners with Flagship Pioneering for Development of Novel Obesity Treatments

Fineline Cube May 11, 2024

Denmark-based pharmaceutical giant Novo Nordisk (CPH: NOVO-B) has announced a partnership with life sciences venture...

Company

Viatris Q1 2024 Results Show Slight Dip in Base Business Brands Amid Overall Stabilization

Fineline Cube May 11, 2024

US pharmaceutical company Viatris (NASDAQ: VTRS) has reported its financial results for the first quarter...

Company Deals

Sanofi Secures Novavax Vaccine Tech in a Deal Valued at Up to USD 1.2 Billion

Fineline Cube May 11, 2024

France’s Sanofi (NASDAQ: SNY) has announced a strategic partnership with protein-based vaccines specialist Novavax (NASDAQ:...

Policy / Regulatory

China Unveils Sweeping 2024 Legislative Plan with Healthcare and Pharma at Forefront

Fineline Cube May 11, 2024

The State Council of China has released its annual legislative work plan for 2024, outlining...

Company Drug

MSD’s Keytruda Adjuvant Treatment for High-Risk Endometrial Cancer Fails to Meet Primary Endpoint

Fineline Cube May 10, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that a late-stage trial for its...

Company

Takeda’s Fiscal 2023 Revenues Grow 1.5%, CEO Weber Forecasts 2025 Profitability After 2024 Dip

Fineline Cube May 10, 2024

Takeda’s (TYO: 4502) annual report for the fiscal year ended March 31, 2024, has been...

Company Drug

WestGene Biopharma’s Groundbreaking mRNA Vaccine for EB Virus Tumors Gets FDA Green Light

Fineline Cube May 10, 2024

WestGene Biopharma Co., Ltd., a biopharmaceutical company based in Chengdu, has announced that its drug...

Company Drug

RJK Biopharma’s RJK002 Earns Tacit Approval for Amyotrophic Lateral Sclerosis Clinical Trial

Fineline Cube May 10, 2024

Shanghai-based RJK Biopharma Ltd. has announced that its Category 1 drug RJK002 has received tacit...

Company Deals Drug

BioNTech Secures Global Rights to Biotheus Inc.’s Pre-Clinical Bispecific Antibody

Fineline Cube May 10, 2024

Biotheus Inc., a biopharmaceutical company based in China, has announced that its German partner BioNTech...

Company Drug

China Grants Marketing Nod to Ferring Pharmaceuticals’ Rekovelle for Assisted Reproduction

Fineline Cube May 10, 2024

Switzerland-based Ferring Pharmaceuticals Ltd announced that its recombinant human follicle stimulating hormone δ injection, Rekovelle,...

Policy / Regulatory

Hong Kong SAR and NMPA Renew Agreements to Boost Drug and Medical Device Regulation

Fineline Cube May 10, 2024

Professor Chung-mau LO, BBS, JP, Secretary for Health of the Hong Kong Special Administrative Region...

Company Drug

Chia Tai Tianqing’s PD-L1 Antibody Benmelstobart Wins NMPA Nod for ES-SCLC

Fineline Cube May 10, 2024

China-based Chia Tai Tianqing has announced that it has received marketing approval from the National...

Company

GSK Shakes Up Leadership with Promotion of Cecilia Qi and Appointment of Sherman Yu

Fineline Cube May 10, 2024

Mike Crichton, Senior Vice President of GlaxoSmithKline (GSK, NYSE: GSK) for the Greater China and...

Company Drug

Sichuan Biokin Pharmaceutical Advances BL-B16D1 to Clinical Trial for Advanced Solid Tumors

Fineline Cube May 10, 2024

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a pharmaceutical company based in China, has announced...

Company Drug

Bio-Thera Solutions’ PD-1 and ADC Combo Gets NMPA Approval for Clinical Trial in Solid Tumors

Fineline Cube May 10, 2024

Bio-Thera Solutions, Ltd (SHA: 688177), a biopharmaceutical company based in China, has announced that it...

Company Drug

Sandoz Q1 2024 Results Highlight 6% Growth, Led by Biosimilars and European Strength

Fineline Cube May 10, 2024

Switzerland-based Sandoz (SWX: SDZ) has reported its financial results for the first quarter of 2024,...

Posts pagination

1 … 387 388 389 … 690

Recent updates

  • Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China
  • Edding Genor’s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib/II Breast Cancer Trial, Targeting TNBC and HR+/HER2- Subtypes
  • Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China
  • Shandong Boan Biotechnology Secures NMPA Approval for Phase II Trial of BA1106/BA1104 Combination in NSCLC, China’s First Non-IL-2-Blocking Anti-CD25 Antibody
  • CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China

Company Drug

Edding Genor’s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib/II Breast Cancer Trial, Targeting TNBC and HR+/HER2- Subtypes

Company Drug

Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China

Company Drug

Shandong Boan Biotechnology Secures NMPA Approval for Phase II Trial of BA1106/BA1104 Combination in NSCLC, China’s First Non-IL-2-Blocking Anti-CD25 Antibody

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.